RANK-ORDER STABILITY ANALYSIS (ROSA) - TESTING PHARMACOECONOMIC DATA

被引:10
作者
EINARSON, TR
ARIKIAN, SR
DOYLE, JJ
机构
[1] HLTH ECON RES,SECAUCUS,NJ 07094
[2] UNIV TORONTO,FAC PHARM,TORONTO,ON M5S 1A1,CANADA
[3] UNIV TORONTO,FAC MED,TORONTO,ON M5S 1A1,CANADA
关键词
PHARMACOECONOMIC ANALYSIS; SENSITIVITY ANALYSIS; ROBUSTNESS; COST-EFFECTIVENESS ANALYSIS; RANK-ORDER STABILITY ANALYSIS;
D O I
10.1177/0272989X9501500407
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
In a pharmacoeconomic analysis, the validity of findings is critical because product ranking may influence formulary decision making. The authors present an approach for examining uncertainty in a pharmacoeconomic analysis that parallels the confidence-interval approach to statistical analysis. This method, rank-order stability analysis (ROSA), is a clear and comprehensive method for validating results of a pharmacoeconomic analysis, as it identifies and evaluates all inputs and values. It is a break-even analysis that identifies the specific point of insensitivity for all parameters analyzed in the pharmacoeconomic model. ROSA is proposed as the preferred method for judging the validity of results derived from estimated parameters in pharmacoeconomic analyses.
引用
收藏
页码:367 / 372
页数:6
相关论文
共 12 条
[1]   A MULTINATIONAL PHARMACOECONOMIC ANALYSIS OF ORAL THERAPIES FOR ONYCHOMYCOSIS [J].
ARIKIAN, SR ;
EINARSON, TR ;
KOBELTNGUYEN, G ;
SCHUBERT, F ;
ALLEN, R ;
BARAN, R ;
BERGMAN, W ;
BITETTO, L ;
BLATTSTEIN, JS ;
BREDA, M ;
CLEMENT, W ;
DECUYPER, C ;
DIFONZO, E ;
VANDOORSLAER, E ;
DOYLE, JJ ;
EFFENDY, I ;
EICHMANN, A ;
FEUILHADE, M ;
FIGUEIREDO, A ;
FLORI, YA ;
GERMAINE ;
CAMARASA, JMG ;
GINTER, G ;
GISBERT, R ;
GOODFIELD, M ;
GROENEWEG, DA ;
GUNN, D ;
HANNUKSELA, M ;
HAVU, V ;
KNAPPE, E ;
KOUSSIDOUEREMONTI, T ;
LATEUR, N ;
LEE, RE ;
LUCIONI, C ;
MATHIOUDAKI, E ;
MIKULITS, R ;
NOLTING, S ;
PANAGIOTIDOU, D ;
PEKURINEN, M ;
PEREIRA, J ;
REY, JP ;
PIETRINI, P ;
SOARES, AP ;
PIRARD, C ;
ROBERTS, DT ;
ROVIRA, J ;
RUFLI, T ;
RUTTEN, F ;
SOMMER, JH ;
SPANGLER, E .
BRITISH JOURNAL OF DERMATOLOGY, 1994, 130 :35-44
[2]  
Drummond M F, 1992, Pharmacoeconomics, V1, P8, DOI 10.2165/00019053-199201010-00004
[3]   COST-EFFECTIVENESS ANALYSIS FOR ONYCHOMYCOSIS THERAPY IN CANADA FROM A GOVERNMENT PERSPECTIVE [J].
EINARSON, TR ;
ARIKIAN, SR ;
SHEAR, NH .
BRITISH JOURNAL OF DERMATOLOGY, 1994, 130 :32-34
[4]   CLINICAL ECONOMICS - A GUIDE TO THE ECONOMIC-ANALYSIS OF CLINICAL PRACTICES [J].
EISENBERG, JM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 262 (20) :2879-2886
[5]  
Freund D A, 1992, Pharmacoeconomics, V1, P20, DOI 10.2165/00019053-199201010-00006
[6]   CONFIDENCE-INTERVALS RATHER THAN P-VALUES - ESTIMATION RATHER THAN HYPOTHESIS-TESTING [J].
GARDNER, MJ ;
ALTMAN, DG .
BMJ-BRITISH MEDICAL JOURNAL, 1986, 292 (6522) :746-750
[7]   GUIDELINES FOR THE CLINICAL AND ECONOMIC-EVALUATION OF HEALTH-CARE TECHNOLOGIES [J].
GUYATT, G ;
DRUMMOND, M ;
FEENY, D ;
TUGWELL, P ;
STODDART, G ;
HAYNES, RB ;
BENNETT, K ;
LABELLE, R .
SOCIAL SCIENCE & MEDICINE, 1986, 22 (04) :393-408
[8]   ECONOMIC-EVALUATION OF PHARMACOLOGICAL THERAPY [J].
HILL, WL .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1986, 20 (7-8) :594-596
[9]   CONFIDENCE-INTERVALS FOR REPORTING RESULTS OF CLINICAL-TRIALS [J].
SIMON, R .
ANNALS OF INTERNAL MEDICINE, 1986, 105 (03) :429-435
[10]   COST-EFFECTIVENESS AND COST-BENEFIT ANALYSES IN THE MEDICAL LITERATURE - ARE THE METHODS BEING USED CORRECTLY [J].
UDVARHELYI, IS ;
COLDITZ, GA ;
RAI, A ;
EPSTEIN, AM .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (03) :238-244